Antibody Information

General Information of This Antibody
Antibody ID
ANI0CHMOC
Antibody Name
Anti-PIEZO1 mAb
Synonyms
AntiPIEZO1 mAb
   Click to Show/Hide
Antibody Type
Monoclonal antibody (mAb)
Antibody Subtype
Humanized IgG1
Antigen Name
Piezo-type mechanosensitive ion channel component 1 (PIEZO1)
  Antigen Info 
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
Anti-PIEZO1-MMAE [Investigative]
 ADC Info 
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 80.00% (Day 27) High PIEZO1 expression (PIEZO1+++)
Method Description
1 x107 TE1 cells were suspended in Matrigel and injected subcutaneously in the right armpit. The treatment of AntiPIEZO1MMAE or control reagents started when the tumor volume reached 300mm3. Treatments for each group were given every 3 days in total four times.
In Vivo Model Esophageal squamous cell carcinoma CDX model
In Vitro Model Esophageal squamous cell carcinoma Esophageal squamous cell carcinoma cells Homo sapiens
References
Ref 1 High-throughput membrane-anchored proteome screening reveals PIEZO1 as a promising antibody-drug target for human esophageal squamous cell carcinoma. Cancer Med. 2022 Oct;11(19):3700-3713.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.